Francisco J. Esteva: The importance of individualized treatment planning based on tumor biology and size
Francisco J. Esteva, Professor of Medicine at Zucker School of Medicine and Chief of Division of Hematology and Medical Oncology at Lenox Hill Hospital, shared on LinkedIn.
“Emerging trends in oncology suggest a shift away from anthracyclines for patients with hormone receptor-positive, HER2-negative, node-negative early breast cancer. However, a deeper look into the TAILORx trial offers important context.
A post-hoc analysis presented by Dr. Nan Chen at SABCS24 revealed that anthracyclines provided significant benefits for patients with an Oncotype Recurrence Score of 31 or higher, particularly when tumors exceeded 2 cm (anatomical stage 2). This finding emphasizes the importance of individualized treatment planning based on tumor biology and size.
These insights remind us that precision oncology continues to evolve, and treatment decisions must be carefully tailored to each patient.
Is the benefit from anthracyclines due to high proliferation, a major component of the Oncotype test? Should we recommend anthracycline and taxane-based chemotherapy, as supposed to anthracycline alone? More questions than answers for an individual patient.
If you are a medical oncologist, what patients with HR+ HER2- node-negative breast cancer would you consider for anthracycline- and taxane-based chemotherapy in the adjuvant setting?”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023